PROGRAM
Invited Speakers
Program
Invited Speakers
  • Program at a Glance
  • Pre-Congress Workshop
  • Scientific Program
  • Invited Speakers
Invited Speakers

All

Day 1: April 25 (Friday)

Day 2: April 26 (Saturday)

  • Search
  • Search initialized
Day 1: April 25 (Friday)
  • Scientific Session I (Ovarian Cancer)
  • April 25 (Fri.), 10:00-11:30 | Hall A
    Role of secondary cytoreductive surgery for recurrent ovarian cancer in the era of PARPi
    Christina Fotopoulou
    Imperial College London, United Kingdom
    CV
    Updated ovarian cancer trials in China
    Rongyu Zang
    Zhongshan Hospital, China
    CV
    Future of clinical trials and translational research
    Jung-Min Lee
    National Cancer Institute, USA
    CV
  • Collaborative Session I - JSGO
  • April 25 (Fri.), 11:00-12:00 | Hall B
    Cervical cancer
    Hideki Tokunaga
    Tohoku Medical University, Japan
    CV
    Endometrial cancer
    Tohru Morisada
    Kyorin University, Japan
    CV
    Ovarian cancer
    Tsukasa Baba
    Iwate Medical University, Japan
    CV
  • Collaborative Session II - CSGO
  • April 25 (Fri.), 13:00-14:00 | Hall A
    The laparoscopic surgery for early stage of cervical cancer: What is the future?
    Yang Xiang
    PUMC Hospital, China
    CV
    The ferltility sparing treatment for endometrium cancer in China
    Jianliu Wang
    Peking University People's Hospital, China
    CV
    Ovarian cancer trials in China
    Rongyu Zang
    Zhongshan Hospital, China
    CV
  • Collaborative Session III - INASGO
  • April 25 (Fri.), 13:00-14:00 | Hall B
    Epidemiology of gynecologic cancer in Indonesia: Shifting cancer burden to the young population
    Yudi Mulyana Hidayat
    Hasan Sadikin General Hospital Bandung, Indonesia
    Optimizing gynecologic cancer management in Indonesia: Addressing disparities and enhancing surgical skills
    Brahmana Askandar
    Airlangga University, Indonesia
    CV
    Future directions in diagnostics and therapy for gynecologic cancer in Indonesia: Implementing molecular testing and targeted therapies
    Tricia Dewi Angggraeni
    Universitas Indonesia, Indonesia
    CV
  • Live Surgery - Ovarian Cancer
  • April 25 (Fri.), 14:20-17:20 | Hall A&B
    Interval cytoreductive surgery for ovarian cancer
    Sang Yoon Park
    National Cancer Center, Korea
    CV
    Robot hybrid cytoreductive surgery
    Myong-Cheol Lim
    National Cancer Center, Korea
    CV
    Primary cytoreductive surgery for ovarian cancer
    Philipp Harter
    Ev. Kliniken Essen-Mitte, Germany
    CV
  • Collaborative Session IV - AOGIN
  • April 25 (Fri.), 15:00-17:00 | Hall B
    Cervical cancer screening based on HPV test
    Shin-Wha Lee
    University of Ulsan, Korea
    CV
    Implementation of primary HPV screening and self-sampling in Thailand
    Wichai Termrungruanglert
    Chulalongkorn University, Thailand
    CV
    The role of extended genotyping in cervical cancer elimination
    Tessa Riandini
    Becton, Dickinson and Company, Singapore
    CV
    Benefits for Asian societies in IPVC 2025 and AI in cervical cancer screening and management
    Siriwan Tangjitgamol
    Vajira Hospital, Thailand
    CV
    Global cervical cancer awareness campaign
    Hyo Sook Bae
    For C Campaign.org, USA
    CV
Day 2: April 26 (Saturday)
  • Scientific Session II (Endometrium)
  • April 26 (Sat.), 09:30-11:30 | Hall A
    Role of adjuvant therapy in early-stage endometrial cancer
    Philipp Harter
    Ev. Kliniken Essen-Mitte, Germany
    CV
    Innovations in molecular subtyping for precision medicine
    Jung-Yun Lee
    Yonsei University, Korea
    CV
    Importance of follow-up of patients with uterine corpus cancer from the perspective of cardio-oncology
    Yoichi Kobayashi
    Kyorin University, Japan
    CV
    Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without Olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA levels, and efficacy in the DUO-E mismatch repair proficient subpopulation
    Jae-Weon Kim
    Seoul National University, Korea
    CV
  • Collaborative Session V - TGCS
  • April 26 (Sat.), 09:30-10:30 | Hall B
    Endometrial cancer
    Atthapon Jaishuen
    Mahidol University, Thailand
    CV
    Ovarian cancer
    Kamaitorn Tientong
    Rajavithi Hospital, Thailand
    CV
    Cervical cancer
    Panwad Ratanasrithong
    National Cancer Institute of Thailand, Thailand
    CV
  • Collaborative Session VI - TAGO
  • April 26 (Sat.), 10:30-11:30 | Hall B
    Focusing on the recent progress of the three major gynecological cancers from a clinical perspective in Taiwan
    Peng-Hui Wang
    Taipei Veterans General Hospital , Taiwan
    CV
    Experience sharing about hyperthermic intraperitoneal chemotherapy for ovarian, fallopian tubal and primary peritoneal cancers in a tertiary referral medical center in Taiwan
    Jen-Ruei Chen
    MacKay Memorial Hospital, Taiwan
    CV
    Fallopian tube organoids: A novel approach for the discovery of early copy number alterations of high-grade serous ovarian cancer
    Hung-Cheng Lai
    Taipei Medical University, Taiwan
    CV
  • Tumor Board
  • April 26 (Sat.), 12:50-14:20 | Hall A
    Siriwan Tangjitgamol
    Vajira Hospital, Thailand
    CV
    Won Kyung Cho
    Sungkyunkwan University, Korea
    CV
    Tricia Dewi Angggraeni
    Universitas Indonesia, Indonesia
    CV
    Hiroyuki Kanao
    Cancer Institute Hospital, Japan
    CV
    Jen-Ruei Chen
    MacKay Memorial Hospital, Taiwan
    CV
    Yang Xiang
    PUMC Hospital, China
    CV
  • Collaborative Session VII - KGOG
  • April 26 (Sat.), 12:50-14:20 | Hall B
    Beginning and past of KGOG: Foundations of progress
    Yong-Man Kim
    University of Ulsan, Korea
    KGOG Today: Advancing gynecologic oncology
    Dae-Yeon Kim
    University of Ulsan, Korea
    CV
    Cervical cancer innovations: KGOG-led studies and outcomes
    Sang Wun Kim
    Yonsei University, Korea
    CV
    Endometrial cancer insights: KGOG-led research contributions
    Jeong-Yeol Park
    University of Ulsan, Korea
    CV
    Ovarian cancer breakthroughs: Spotlight on KGOG-led studies
    Chel Hun Choi
    Sungkyunkwan University, Korea
    CV
    Overview of the 400X protocol: Insights from the surgery and DDT committee
    Eun-Ju Lee
    Chung-Ang University, Korea
    CV
    Collaborating for progress: KGOG’s role in NRG studies
    Min Kyu Kim
    Sungkyunkwan University, Korea
    CV
    Expanding horizons: KGOG's participation in GOG-partners research
    Jae Yun Song
    Korea University, Korea
    CV
    Global collaboration in gynecologic Oncology: KGOG in ENGOT, JGOG, and EAGOT initiatives
    Min Chul Choi
    University of Ulsan, Korea
    CV
  • Debate Session
  • April 26 (Sat.), 14:40-16:10 | Hall A
    "Optimal surgical approach for early-stage cervical cancer" - Favor minimally invasive surgery
    Yang Xiang
    PUMC Hospital, China
    CV
    "Optimal surgical approach for early-stage cervical cancer" - Favor open surgery
    Philipp Harter
    Ev. Kliniken Essen-Mitte, Germany
    CV
    "How to improve survival outcome in locally advanced cervical cancer" - Favor addition of neoadjuvant chemotherapy or immune check point inhibitor to CCRT
    Christina Fotopoulou
    Imperial College London, United Kingdom
    CV
    "How to improve survival outcome in locally advanced cervical cancer" - Favor addition of debulking surgery to CCRT
    Ju-Won Roh
    CHA University, Korea
    "Optimal management of recurrent cervical cancer in irradiated pelvis" - Favor surgical management including pelvic exenteration
    Hiroyuki Kanao
    Cancer Institute Hospital, Japan
    CV
    "Optimal management of recurrent cervical cancer in irradiated pelvis" - Favor non-surgical management
    Jen-Ruei Chen
    MacKay Memorial Hospital, Taiwan
    CV
  • Collaborative Session VIII - KGCR
  • April 26 (Sat.), 14:40-16:10 | Hall B
    Translational research approaches utilizing PDX and PDO models in gynecologic cancer
    Jeong-Won Lee
    Sungkyunkwan University, Korea
    CV
    Development of novel personalized medicine for ovarian clear cell carcinoma
    Shogo Shigeta
    Tohoku University, Japan
    CV
    Therapy of drug resistant ovarian cancer
    Jae Ho Kim
    Pusan National Unviersity, Korea
    CV
    New findings of basic research on PARP and functional analysis of SLFN11 related to therapeutic effect of PARP inhibitors
    Junko Murai
    Center for Proteoscience, Ehime University, Japan
    CV